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Tuberculosis (TB) remains a major health threat. Although a vaccine has been available
for almost 100 years termed Bacille Calmette-Guérin (BCG), it is insufficient and better
vaccines are urgently needed. This treatise describes first the basic immunology and
pathology of TB with an emphasis on the role of T lymphocytes. Better understanding
of the immune response to Mycobacterium tuberculosis (Mtb) serves as blueprint for
rational design of TB vaccines. Then, disease epidemiology and the benefits and failures
of BCG vaccination will be presented. Next, types of novel vaccine candidates are
being discussed. These include: (i) antigen/adjuvant subunit vaccines; (ii) viral vectored
vaccines; and (III) whole cell mycobacterial vaccines which come as live recombinant
vaccines or as dead whole cell or multi-component vaccines. Subsequently, the major
endpoints of clinical trials as well as administration schemes are being described. Major
endpoints for clinical trials are prevention of infection (PoI), prevention of disease (PoD),
and prevention of recurrence (PoR). Vaccines can be administered either pre-exposure
or post-exposure with Mtb. A central part of this treatise is the description of the viable
BCG-based vaccine, VPM1002, currently undergoing phase III clinical trial assessment.
Finally, new approaches which could facilitate design of refined next generation TB
vaccines will be discussed.
Keywords: tuberculosis, vaccine, Bacille Calmette-Guérin, subunit, biomarker, macrophage, T lymphocyte,
clinical trial
“ Commit to advancing research for basic science, public health research and the development of innovative
products and approaches, . . ., without which ending the tuberculosis epidemic will be impossible, including
towards delivering, as soon as possible, new, safe, effective, equitable, affordable, available vaccines, . . .”
Resolution adopted by General Assembly of the United Nations from the High Level Meeting on the
fight against TB, 2018 (1).
INTRODUCTION
The only tuberculosis (TB) vaccine in use until today, Bacille Calmette Guérin (BCG), was
introduced in 1921 after intensive research & development (R&D) for more than a decade (2).
It was not the first tryout to immunize against TB. The very first attempt was made by Robert
Koch who used a subunit-adjuvant formulation (3). Subsequently, several other approaches were
Frontiers in Immunology | www.frontiersin.org 1 February 2020 | Volume 11 | Article 316
fimmu-11-00316 February 25, 2020 Time: 19:18 # 2
Kaufmann Vaccination Against Tuberculosis
tested including killed mycobacterial vaccines and live non-
tuberculous mycobacterial strains. Yet, these all failed and the
only vaccine with proven safety and efficacy until today remains
BCG. In fact, today BCG is the most widely used vaccine,
which has been given more than 4 billion times. BCG was
developed to protect newborns at high risk of TB (2). This
mission has been accomplished at least partially since BCG
was proven to protect against severe extra pulmonary, but
less against pulmonary TB in infants (4–6). Yet, even today
infant TB takes a worrisome toll in TB endemic countries with
high coverage of BCG immunization (7–9). Later, BCG was
also tested as a vaccine against pulmonary TB in adolescents
and adults, but this ambitious target was not reached and
no vaccine has ever succeeded in reliably protecting against
pulmonary TB, the most prevalent form of the disease, in any age
group. A better vaccine is urgently needed since Mycobacterium
tuberculosis (Mtb), the cause of TB, remains on top of the
infamous list of deadly infectious agents (10). In 2018, 10 million
individuals fell ill with this disease and 1.5 million died (11)
(Figure 1). The early 21st century has witnessed increasing
R&D efforts for novel TB vaccines (12–19). These include
subunit-adjuvant formulations comprising fusion proteins of
Mtb, viral vectored vaccines expressing one or more antigens




Tuberculosis is a chronic infectious disease caused by the
intracellular pathogen Mtb (20). This acid-fast bacillus is shielded
by a unique lipoid-rich cell wall containing various wax-like
substances and glycolipids which contribute to resistance against
immune attack. Mtb is generally transmitted by aerosols in which
it enters alveoli in lower lung lobes. Once the pathogen has been
engulfed by alveolar phagocytes, it ends up in a phagosome,
where it keeps the local pH neutral (21). Moreover, Mtb is capable
of egressing into the cytosol (22). These and other mechanisms
facilitate resistance of Mtb to professional phagocytes including
polymorphonuclear neutrophilic granulocytes (in short
neutrophils) and mononuclear phagocytes (tissue macrophages
and monocytes) (23–27). Resting tissue macrophages generally
fail to eliminate Mtb and serve as its retreat due to their long
lifespan. Blood monocytes are slightly more aggressive but
fail to achieve sterile elimination of Mtb. Neutrophils are
highly aggressive phagocytes with the potential to harm Mtb.
Due to their short lifespan, they generally will not succeed in
completely eliminating Mtb and they do not serve as a harbor,
in which Mtb can persist. Once activated by cytokines, notably
Interferon-γ (IFN-γ), mononuclear phagocytes increase their
anti-bacterial capacities and pose a more serious threat to Mtb
although they generally fail to eradicate it completely. The
innate immune response mediated by professional phagocytes
serves as a first barrier for Mtb. Recent evidence suggests that
epigenetic changes induced by Mtb in professional phagocytes
leads to trained immunity. Such trained immunity could play
a role in early defense against repeated Mtb infections (28,
29). However, thus far compelling evidence for this notion is
still incomplete.
In addition, subtypes of dendritic cells (DC) can engulf Mtb
(30, 31). They likely translocate Mtb into the lung parenchyma,
where the formation of a granuloma is initiated.
Granuloma formation is strongly regulated by T lymphocytes
originally stimulated in the draining lymph nodes to which
DC harboring Mtb navigate (25, 32). T lymphocytes orchestrate
formation of solid granulomas which are primarily composed
of macrophages, DCs, and T and B lymphocytes. Within these
granulomas Mtb is contained and the infected individual remains
healthy and develops latent TB infection (LTBI) (24, 33, 34). CD4
T cells have been proven to be central to acquired resistance
against and containment of Mtb (19, 25). According to the
cytokines, these CD4 T cells secrete, they can be categorized into
TH1, TH2, and TH17 cells. TH1 cells are preferentially stimulated
during Mtb infection and are of major importance for defense.
They produce cytokines such as IFN-γ, interleukin-2 (IL-2) and
tumor necrosis-α (TNF-α). TH2 cells are only weakly induced.
They are often considered harmful in TB since they induce
inappropriate effector mechanisms. Their major cytokines are
IL-4, IL-5, IL-10, and IL-13. However, evidence has been provided
that TH2 cytokines, at least in part, can contribute to tissue
healing. TH17 cells induce rapid proinflammatory responses by
secreting IL-17. They are stimulated during Mtb infection and
evidence has been published that they participate in protection
against TB, notably at early stages of infection. The role of
CD8 T cells in protection and containment – although less
profound – is also widely accepted. CD8 T cells often produce
cytokines of TH1 type and in addition express cytolytic activity
(19, 25, 26). Contribution of cytolytic mechanisms to killing of
Mtb has been demonstrated (35). The role of other lymphoid
cells including innate lymphoid cells (iLC), NK T cells, mucosa
associated immune T cells (MAIT), γδ T lymphocytes, and B
lymphocytes is a matter of ongoing discussion (32, 36–45). B
lymphocytes could participate in immunity against TB via two
mechanisms: First, as regulatory B lymphocytes and second
as antibody producing plasma cells. Evidence for regulatory
B lymphocytes in immunity against TB is scarce (46, 47).
A role for distinct antibody isotypes in defense against TB has
been provided (36, 42, 45). Perhaps these antibodies modulate
professional phagocytes through their binding to distinct Fc
receptors. Convincing evidence has been generated that γδ T
cells contribute to early immune defense by secreting IL-17
(38). The iLC can be categorized into iLC-1, iLC-2 and iLC-3
according to their cytokine secretion pattern (40). Cytokines
produced by iLC-1 are of TH1 type, iLC-2 cytokines are of
TH2 and iLC-3 cytokines are of TH17 type. The iLC-1 and
iLC-3 probably contribute to resistance to Mtb and the iLC-2
to healing of lesions (37). During chronic infection, canonical
CD4 and CD8 T lymphocytes develop into memory T cells which
can be grouped into effector memory T cells (TEM), central
memory T cells (TCM), and tissue resident memory T cells
(TRM) (48). Although the role of the different memory T cells
in protection against Mtb is incompletely understood, evidence
for a particular role of TRM and TCM in protection against Mtb
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FIGURE 1 | Epidemiologic data for tuberculosis (TB).
has been provided (49, 50). It is likely that different types of
memory T cells participate in protective immunity at different
stages of infection.
During LTBI, Mtb is contained in solid granuolomas
(24, 33, 51). LTBI transforms into active TB disease when
granulomas become necrotic and then caseous. This happens
in about 5% of individuals with LTBI within the first 2 years
and in another 5% at later time points. Thus, only ca. 10%
of the 1.7 billion individuals with LTBI develop active TB
disease (52). Progression to active disease is due to weakening
of the immune response via several incompletely understood
mechanisms. It is likely that myeloid-derived suppressor cells and
regulatory T lymphocytes participate in dampening of protective
immunity (53, 54). These cells produce inhibitory cytokines
including IL-4, IL-10, and transforming growth factor-β (TGF-β).
Moreover, excessive checkpoint control through inhibitory
surface molecules including PD-1/PDL-1 and CTLA-4/B7
co-receptor interactions is likely involved (55, 56).
Notably, progression to active TB from LTBI must be viewed
as a continuum rather than a discrete step from one to another
stage (33, 57, 58). Mtb is transmitted from a TB patient to a
healthy individual in a metabolically active and replicative stage.
Hence, the host first encounters highly active Mtb (24). During
LTBI, Mtb changes from a metabolically active and replicative
stage into a dormant stage in which its activities are markedly
downregulated. Once progression to active TB has ensued, Mtb
wakes up and becomes active again.
At the early stage of infection, it is possible that Mtb is rapidly
eradicated before stable LTBI develops, but the proportion
of individuals who become transiently infected, sometimes
accompanied by a short episode of clinical symptoms remains
unclear (51, 57, 59). Recent evidence suggests LTBI is succeeded
by incipient TB, in which the host remains healthy, but becomes
alerted and Mtb regains its metabolic and replicative activities
(59–62). Subsequently, subclinical TB evolves in which first
signs of pathology occur although clinically the patient appears
healthy. Signs of host vigilance and pathology can be detected
by sensitive gene expression and metabolic profiling (26, 60–
62). Given that most, if not all, cases of subclinical TB progress
to active TB disease which can be clinically diagnosed, it is
possible to predict disease by sensitive profiling by means
of transcriptomics and metabolomics (60–63). Note that the
different stages are not discrete and that in a single patient
areas reflecting LTBI (solid granulomas containing dormant
Mtb), incipient TB (solid to necrotic granulomas in which
Mtb regains its metabolic and replicative activity), subclinical
TB (further increase in pathology due to transition of some
solid granulomas to necrotic ones and eventually first signs
of caseation) and active TB (all three forms of granulomas
present with a preponderance toward caseation and cavitation)
can coexist. Accordingly, different stages of granulomas ranging
from solid form to caseation and cavitation coexist, as well (58).
Obviously, the coexistence of different pathologies and different
Mtb activities render TB immunopathology highly complex.
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BOX 1 | Major vaccine candidates in clinical trials.
Different types of TB vaccines have entered the clinical trial pipeline. These are: viral vectored protein antigens of Mtb, fusion protein antigens of Mtb in adjuvants,
killed whole mycobacterial cell vaccines, and recombinant viable mycobacterial vaccines. The viral vectored and the adjuvanted protein vaccines are subunit
vaccines, which are generally considered to boost a prime with BCG. The viable TB vaccines are considered for BCG replacement or for boosting previous BCG
prime. Killed whole cell vaccines are sometimes considered for booster vaccination and more often for TB therapy in adjunct to chemotherapy.
• Viral vectored vaccines include MVA85A, a modified vaccinia Ankara (MVA) vaccine expressing antigen Ag85A of Mtb. First phase IIb efficacy trials with
this vaccine in neonates and in adults failed to provide protection (102, 103). More recently, the vaccine has been tested for safety and immunogenicity
after aerosol application (104, 105). Other viral vectored vaccines include replication deficient adenovirus vectors expressing antigen Ag85A and
a replication deficient H1N1 influenza vector expressing antigen Ag85A and ESAT-6. Novel prime boost schedules are also being tested including
adenovirus vectors for prime and MVA vector for boost expressing antigen Ag85A.
Major viral vectored candidates undergoing clinical testing are:
Ad5Ag85A (phase I), a replication-deficient adenovirus (Ad) 5 vector expressing Antigen 85A (106, 107).
ChAdOx1.85A + MVA85A (phase I), a prime/boost regimen comprising prime with a chimpanzee Adenovirus (ChAd) expressing Antigen 85A
(ChAdOx1.85A) followed by a boost with modified Vaccinia Ankara virus (MVA) expressing Antigen 85A (108).
TB-FLU-04L (phase IIa), a replication-deficient H1N1 influenza virus strain expressing Antigen 85A and ESAT-6 (109).
• Protein adjuvant formulations undergoing clinical testing include:
Hybrid 1 (H1, phase I completed) comprising either IC31 or CAF01 as adjuvant and a fusion protein of Antigen 85B and ESAT-6 as antigen (110, 111).
H4 (phase II completed) and H56 (phase IIb) formulated in IC31 as adjuvant and fusion proteins of Antigen 85B and TB10.4 (H4) or Antigen 85B, ESAT-6
and Rv2660c (H56) (73, 112–114).
ID93 (phase IIa) composed of GLA-SE as adjuvant and a fusion protein of 4 antigens, namely Rv2608, Rv3619, Rv3620 and Rv1813 (115, 116).
M72 (phase IIb completed) composed of AS01E as adjuvant and a fusion protein of 2 antigens, Rv1196, and Rv0125. M72 has completed a phase IIb
trial revealing its partial protective efficacy (for further details see text) (65, 66, 117).
• Compositions of adjuvants:
IC31, cationic peptides plus TLR-9 agonist;
CAF01, cationic liposome vehicle plus immunomodulatory glycolipid;
GLA-SE, Squalen oil-in-water emulsion plus TLR-4 agonist;
AS01E, liposomes with monophosphoryl lipid A plus saponin QS21.
• Viable vaccines undergoing clinical testing are:
MTBVAC (phase IIa completed), a genetically attenuated Mtb vaccine (118, 119).
VPM1002 (several phase III trials), a rBCG vaccine (for further details see text) (84, 85).
• Killed whole cell vaccines include:
DAR-901 (killed M. obuense) which had already completed a phase III trial under a different name (120–123) and is now under re-evaluation (phase I
trial completed) (124).
MIP (phase III) based on killed M. indicus pranii organisms (125–127).
M. vaccae (phase III) based on killed M. vaccae (128–132).
RUTI (phase IIa) a purified killed vaccine of Mtb fragments (133–135).
• Therapeutic vaccines: The above vaccine trials assess outcome of preventive vaccination. Several candidates are also tested as therapeutic vaccines
either for TB treatment in adjunct to canonical chemotherapy or for PoR of TB patients who were cured from TB by canonical chemotherapy but may
undergo recurrence (136).
Therapeutic vaccines in clinical trials include:
H56:IC31 (phase I), a subunit protein formulation;
ID93:GLA-SE (phase I), a subunit protein formulation;
RUTI (phase IIa), a purified killed vaccine of Mtb fragments;
TB-FLU-04L (phase IIa), a viral vectored vaccine;
MIP (phase III completed), a killed M. indicus pranii preparation;
M. vaccae (phase III completed), a killed M. vaccae preparation;
VPM1002 (phase III), a live rBCG vaccine.
CURRENT STATUS OF TUBERCULOSIS
EPIDEMIOLOGY AND THE
TUBERCULOSIS VACCINE PIPELINE
According to the latest TB report of the World Health
Organization (WHO), 10 million individuals developed active
TB disease and 1.5 million died of TB in 2018 (11). Globally
1.7 million individuals are Mtb infected (LTBI, incipient TB,
subclinical TB) (52). Thus, the goal of the WHO to eliminate
TB over the next decades requires much better intervention
measures and notably a highly efficacious vaccine (10). BCG
fails to protect against pulmonary TB, which is not only the
most prevalent form of disease but also the major source of
transmission. This has led to several attempts to design novel
vaccination regimens (18). Numerous vaccine candidates have
entered clinical trials and first promising results have been
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obtained (see below). Current vaccine candidates undergoing
clinical testing are viral vectored vaccines expressing a few Mtb
antigens, adjuvanted subunit vaccines typically comprising fusion
proteins representing two to four Mtb antigens, killed whole cell
vaccines and viable whole cell vaccines. Further details can be
found in Box 1. The vaccine candidates are tested in different
clinical situations. These are:
(i) Prevention of Infection (PoI): This clinical endpoint can
be applied for pre-exposure vaccination, i.e. vaccination
of individuals who have not yet encountered Mtb. The
most important target group for PoI are neonates. The
WHO has prioritized a vaccine to lower the risk of Mtb
infection (11).
(ii) Prevention of Disease (PoD): It is obvious that PoI will
result in PoD. The major target population for PoD,
however, are individuals with LTBI. Cutting the risk of TB
disease in individuals with LTBI has also been prioritized
by the WHO (11).
(iii) Prevention of Recurrence (PoR): In high endemic areas,
ca. 10% of TB patients who had been cured by
canonical drug treatment undergo recurrence, either due
to reinfection or relapse (64).
(iv) Therapeutic Vaccination in Adjunct to Canonical Drug
Treatment: Such a vaccination regimen gains increasing
importance for patients with multi or extensively drug-
resistant TB (MDR / XDR-TB) (16). An estimated half
million of active TB patients suffer from MDR-TB
and 50,000 to 100,000 individuals from XDR-TB (1).
Vaccines for PoR are sometimes considered as therapeutic
vaccines, as well.
This review will focus on vaccines that prevent active TB either
through PoI, PoD, or PoR.
PREVENTION OF DISEASE BY THE
SUBUNIT VACCINE M72 IN A PHASE IIb
CLINICAL TRIAL
The M72 vaccine candidate developed by GlaxoSmithKline
has successfully completed a phase IIb clinical trial (65, 66).
Participants of this study were HIV− adults with LTBI who had
been immunized with BCG as infants. Hence, the study was a
post-exposure booster immunization with a subunit vaccine with
PoD as clinical endpoint. The clinical endpoint was determined
after 2 years of follow-up as pulmonary TB in absence of
HIV infection (66). The study revealed ca. 50% protection over
placebo control. The follow-up study confirmed the efficacy after
the third year (65). This is the first vaccine trial to provide
evidence for PoD in human TB. A positive control with BCG was
not included in this study. It is hoped that global gene expression
profiling and immunologic data will provide information about
potential mechanisms underlying PoD induced by this vaccine.
The vaccine comprises two TB antigens formulated in a potent
adjuvant, AS01E (see Box 1). This adjuvant had been developed
as part of the adjuvant system (AS) series and is also used in the
shingles vaccines, Shingrix, and the malaria vaccine, Mosquirix
(67). Availability of AS01E is limited and production cost is high. It
has to be seen whether and how these limitations affect supply of
this vaccine for broad-scale immunization programs. Satisfactory
supply of vaccines for poverty-related diseases including TB and
malaria strongly depends on an affordable price (68).
PROMISING PREVENTION OF DISEASE
DATA IN NON-HUMAN PRIMATES (NHP)
BY A VIRAL VECTORED TUBERCULOSIS
VACCINE CANDIDATE
Cytomegalovirus (CMV) based vaccines have been studied in
a number of infectious diseases (69). Notably, in a simian
immunodeficiency virus (SIV) model of rhesus macaques, CMV
vectored vaccines expressing SIV antigens have shown profound
protection mediated by CD4 and CD8 T lymphocytes (69).
These T cells have been characterized as effector TEM cells and
transitional effector memory T cells. Based on these findings, a
TB vaccine candidate was designed which is based on a CMV
vector expressing 6 or 9 Mtb antigens (70). This vector has been
tested for PoD in rhesus macaques and was shown to induce
profound protection against TB disease (70). Importantly, in a
proportion of animals, evidence for sterile eradication of Mtb
by this CMV-vectored TB vaccine was obtained. As expected,
the vaccine induced profound CD4 and CD8 T cell responses as
well as marked IFN-γ and TNF secretion. In contrast, antibody
responses were not induced significantly. The protective CD8
T cell population was not only restricted by MHC I, but
also by MHC-E or MHC II. BCG administered intradermally
also induced protection, albeit weaker. Intriguingly, prime with
BCG and boost with the CMV-based TB vaccine reverted
the strong protective effect of the CMV vaccine to levels
of protection induced by BCG. Gene expression profiling of
vaccinated animals indicated a role for neutrophils in protection
induced by the CMV vectored TB vaccine. In conclusion, despite
certain disadvantages of CMV-vectored vaccines in general, the
CMV-based TB vaccine represents a promising candidate which
deserves further investigation. Obviously, the nullifying effect
of BCG prime on protective efficacy induced by the CMV
TB vaccine boost needs particular attention. Neonatal BCG
immunization is done routinely in high TB endemic areas as part
of the expanded program of immunization (EPI) recommended
by WHO. Hence a new vaccine that provides no added value for
BCG-immunized individuals will face major issues before it can
be further developed. Similarly, a recent study revealed that in
NHP boosting BCG with M72 or H56 (see Box 1) vaccines failed
to enhance protection induced by BCG (71).
RECENT FINDINGS WITH THE
CANONICAL BACILLE
CALMETTE-GUÉRIN VACCINE
Two recent studies on BCG immunization have revealed
marked impact of the vaccination regimen (72, 73). In the
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first study, NHP were immunized with BCG intravenously (72).
Earlier research in the 1970s had already provided compelling
evidence that intravenous immunization with live BCG induces
superior protection against TB as compared to other routes of
administration in NHP with evidence for sterile eradication of
Mtb (74, 75). Thus, in one study 3/3 animals were markedly
protected against TB as measured by hematogenous spread,
lymphadenopathy and lung involvement (74). On the other
hand, profound splenomegaly was reported after intravenous
administration of live BCG. Probably this significant adverse
event was the major reason that such studies were not followed
up. Only very recently this approach was investigated in greater
depth. It was shown that intravenous immunization of NHP
with BCG induced more profound protection than intradermal
or aerogenic vaccination (72). Indeed, from a proportion of
animals receiving BCG by the intravenous route no Mtb could
be recovered. This study also included a series of highly
sophisticated immunologic and pathologic analyses. It was found
that antigen responses of CD4 and CD8 T lymphocytes were
induced substantially by intravenous immunization prior to
Mtb challenge, whereas γ/δ T cells and MAIT cells were,
similarly, activated as in groups receiving other routes of
immunization. The T cell response was mostly of TH1 type
with some contribution of TH17 type. On the negative side,
splenomegaly was observed after intravenous immunization
with a ca. twofold enlargement of spleens compared to
controls. However, splenomegaly was transient and 6 months
after BCG immunization no differences were observed in
spleen size across the different experimental groups including
intravenous administration. Six months after immunization,
animals were challenged with a low dose of Mtb. Positron
emission tomography – computed tomography (PET/CT) scans
revealed fewer granulomas in the intravenously immunized
animals compared to controls. These findings provide proof
of concept that BCG immunization can induce profound, in
some cases sterile, protection in NHP. It needs to be seen how
far the splenomegaly observed will be prohibitive for clinical
studies in humans.
The second recent study tested the outcome of BCG
booster vaccination in Mtb unexposed adults (73). Booster
vaccination with BCG had been performed previously although
generally it was not endorsed because of the potential risk of
adverse events. This assumption was largely based on anecdotal
reports describing occasional adverse events after repeated BCG
immunization in individuals with LTBI and frequent severe
events in TB patients. Principally, BCG revaccination in Mtb
uninfected individuals does not cause major side effects and
in the recent formal clinical trial, BCG revaccination of Mtb
unexposed individuals demonstrated partial prevention of stable
Mtb infection (73). More precisely, exposure was determined
indirectly via an IFN-γ release assay (IGRA) which determines
IFN-γ secretion by canonical T cells after in vitro restimulation
with Mtb specific antigens (76–78). This assay is mostly based
on CD4 T cell responses with some contribution of CD8 T
cells. Whilst initial IGRA conversion did not differ between
BCG immunized and untreated study participants, sustained
IGRA conversion was significantly reduced by ca. 45% in BCG
immunized study participants over controls (73). These findings
can be interpreted to mean that stable Mtb infection is prevented
by BCG revaccination although in fact it is based on reduced T
cell responses as measured by IGRA. It remains to be established
more precisely whether prevention of sustained IGRA conversion
directly translates into long-term PoI and consequently PoD.
Previous observational studies had evaluated PoD by BCG
revaccination based on epidemiologic data. Generally, they
did not find significant differences between controls and BCG
revaccinated individuals (79–81).
These two studies provide strong evidence that the
outcome of BCG vaccination is markedly influenced by
the kind of administration, notably route of immunization
(intravenous) and type of vaccine schedule (pre-exposure
revaccination). In conclusion, the BCG vaccine still provides
room for improvement.
VPM1002
One of the most advanced TB vaccines, VPM1002, was improved
by genetic modification (82). VPM1002 is a recombinant BCG
(rBCG) which expresses listeriolysin from Listeria monocytogenes
and is devoid of urease C (83). Development of this vaccine had
started in the 1990s with the aim to improve BCG by endowing
it with the capacity to stimulate a broader, more efficacious
T cell response.
VPM1002 has successfully completed phase I and phase IIa
clinical trials proving its safety and immunogenicity in adults and
neonates (84, 85). A phase II clinical trial in HIV exposed and
unexposed neonates has been completed and awaits unblinding
(NCT 02391415). A phase III clinical trial in HIV exposed and
unexposed neonates is being prepared and expected to start
in 2020. This trial has been designed as pre-exposure BCG
replacement for infants with PoI as clinical endpoint. In this
clinical trial, termed priMe, neonates will be immunized with
VPM1002 or BCG as comparator at several sites in Sub-Saharan
Africa. A phase III clinical trial with VPM1002 assessing PoR
is currently ongoing in India (NCT 03152903). For this trial,
patients with TB who had been cured by drug treatment are being
recruited. An estimated 10 % of these individuals will develop
active TB disease due to reinfection or relapse within 1 year after
completion of drug treatment. The clinical trial therefore will
reveal whether vaccination with VPM1002 given 3 months after
completion of drug treatment can prevent recurrence. A phase
III household contact trial has been launched in July 2019 by
the Indian Council for Medical Research (ICMR), in which
VPM1002 and another vaccine candidate (MIP, see Box 1) will
be assessed for PoD in household contacts of patients with
active pulmonary TB disease. In addition, VPM1002 is also being
assessed as therapeutic agent against non-muscle invasive bladder
cancer as substitute for BCG (NCT 02371447). The canonical TB
vaccine BCG is the preferred immunomodulatory medicine for
treatment of bladder cancer and the current clinical trial assesses
whether VPM1002 is safer than and at least equally efficient
as BCG against recurrence of bladder cancer. In conclusion, a
century after the introduction of the original vaccine BCG, there
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is hope for a revival of an improved BCG-based TB vaccine.
A rationally revamped BCG could contribute to the solution
of the TB crisis.
HOW DOES THE INTRACELLULAR
BEHAVIOR DIFFER BETWEEN VPM1002,
BACILLE CALMETTE-GUÉRIN, AND
Mtb?
Both BCG and Mtb reside in phagosomes, which are arrested at
an early stage by neutralization of the phagosomal pH to prevent
its acidification (21). Consequently, phagolysosome fusion is
diminished. Yet, BCG is degraded in the phagosome whereas
Mtb survives in phagocytes for prolonged periods of time. Only
recently, virulence mechanisms of Mtb absent from BCG have
been elucidated. Although several sub-strains of BCG exist,
it is now clear that the critical step which occurred during
attenuation of the parental Mycobacterium bovis strain was
the loss of the region of difference (RD) 1 which encodes a
number of gene products mediated through the ESX/type VII
secretion system and capable of perturbating the phagosomal
membrane (86). Membrane perturbation by the RD-1 gene
products of Mtb leads to inflammasome activation, apoptosis
and autophagy (Figure 2). The signaling cascades involve nod-
like receptor protein 3 (NLRP-3) and absent in melanoma
2 (AIM-2), responsible for IL-1 and IL-18 processing from
their respective precursor molecules by the inflammasome as
well as STING responsible for autophagy and type I IFN
dependent responses (87). STING senses cyclic guanosine
monophosphate-adenosine monophosphate (cGAMP) derived
from double-stranded DNA of Mtb via the enzyme cyclic
guanosine monophosphate-adenosine monophosphate synthase
(cGAS). All these sequelae are caused by Mtb but not
or less so by BCG.
For the design of VPM1002, BCG was equipped with
listeriolysin from L. monocytogenes which facilitates perturbation
of the phagosomal membrane thereby inducing stronger T
cell responses (83). Listeriolysin is a thiol-activated perforin,
which perforates cholesterol containing membranes at an acidic
pH (88–90). This pH restriction generally prevents listeriolysin
activity in the extracellular milieu with neutral pH, e.g. blood and
interstitial space. It is however, achieved during natural infection
of phagocytes with L. monocytogenes which allows secretion
of biologically active listeriolysin. Because BCG neutralizes
the phagosomal compartment, acidification is not achieved.
For this reason, the urease C encoding gene was deleted
in VPM1002 (83). This enzyme is responsible for ammonia
production and thereby participates in neutralization of the
phagosome where BCG resides (21). Accordingly, VPM1002
lacking urease C favors phagosomal acidification and thereby
secretion of biologically active listeriolysin (Figure 2). Once
listeriolysin has reached the cytosol, it is rapidly degraded. This
is due to the amino acid sequence proline-glutamate-serine-
threonine (PEST) in the listeriolysin amino acid sequence which
promotes its ubiquitination (Figure 3) (88–90). This represents
an inbuilt safety mechanism, which restricts listeriolysin-activity
to the perturbation of the membrane of the phagosome, where
VPM1002 resides and prevents further potentially detrimental
effects on cell membranes. The RD-1 encoded machinery of Mtb
is not endowed with such a safety mechanism.
Similar to the RD-1 machinery in Mtb, listeriolysin-mediated
perturbation of the phagosomal membrane by VPM1002 results
in inflammasome activation through AIM-2 (91). Hence, IL-1
and IL-18 are processed from their respective precursors.
These proinflammatory cytokines create a milieu favorable for
activation of TH1 and TH17 cells. Listeriolysin also facilitates
autophagy via AIM-2 and STING by promoting sensing of
double-strand mycobacterial DNA derived from VPM1002 via
cGAS and cGAMP after its egress into the cytosol (91).
In addition, membrane perturbation by listeriolysin causes
apoptosis, which leads to cross priming of T cells (92). Together
these mechanisms improve vaccine efficacy of VPM1002 as
compared to canonical BCG (82, 93). Moreover, VPM1002
was shown to be safer than BCG in preclinical studies (83).
In experimental models improved stimulation of both CD4
and CD8 T cells has been demonstrated (92) as well as more
profound activation of TH17 cells in addition to TH1 cells
(94). In addition, central memory T cells were more strongly
stimulated by VPM1002 as compared to canonical BCG (50).
Finally, VPM1002 was shown to stimulate higher serum levels
of specific antibodies both in animal models and in human (50,
84, 85). In conclusion, VPM1002 stimulates an immune response
of more depth and breadth and at the same time expresses lower
virulence as compared to BCG (82).
LEARNING FROM INDIVIDUALS
RESISTANT TO STABLE Mtb INFECTION
AND THOSE CAPABLE OF ERADICATING
Mtb AFTER STABLE INFECTION
Individuals with LTBI are generally identified by tuberculin
skin test (TST) or IGRA (Figure 4) (76–78). Accordingly,
identification of the 1.7 billion individuals on this globe with
LTBI is based on measurements of T cell responses against Mtb
antigens. These antigens are relatively undefined mixtures of Mtb
proteins (purified protein derivative, PPD) in the case of TST and
well defined Mtb proteins and/or peptides in the case of IGRA.
Several lines of evidence suggest that a distinct population
of individuals remain Mtb uninfected despite their close and
prolonged contact with patients with active pulmonary TB who
continuously expel Mtb (95–98). This notion is based on the
finding that such individuals do not convert when tested by
TST or IGRA. Assuming that the lack of the canonical immune
response determined by TST and/or IGRA reflects absence of
Mtb infection, the following scenario arises (Figure 3): Initially,
household contacts of a patient with active pulmonary TB fall
into two groups; those who are already LTBI because of previous
contact and hence are TST+/IGRA+, and naïve individuals who
are TST−/IGRA−. Due to the intensive contact, most of the
naïve individuals will convert to TST+/IGRA+ and most of them
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FIGURE 2 | Major mechanisms underlying induction of the host immune response by VPM1002 and M. tuberculosis (Mtb) (for further details see text). (A) VPM1002.
VPM1002 (rBCG1ureC::Hly) expresses listeriolysin and lacks urease C activity. Following phagocytosis, VPM1002 ends up in a phagosome. Principally phagosomes
(Continued)
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FIGURE 2 | Continued
become acidic after uptake of particles, but BCG and Mtb actively keep the phagosomal pH neutral. Due to the absence of ureaseC in VPM1002, acidification takes
place. This facilitates perturbation of the phagosomal membrane by biologically active listeriolysin. (1) Membrane perturbation allows egress of antigens into the
cytosol for processing through the MHC class I pathway. (2) Perturbation can lead to apoptosis. (3) Double-strand DNA released into the cytosol is sensed by
absence in melanoma 2 (AIM2). (4) AIM2 activates the inflammasome to generate IL-1β and IL-18. (5) Cyclic GMP-AMP synthase (cGAS) is formed which is then
transformed into cyclic guanosine monophosphate-adenosine monophosphate (cGAMP). (6) The latter molecule is sensed by stimulator of IFN genes (STING) which
induces autophagy and type I IFN responses. (7) Antigen egress into the cytosol allows stimulation of CD8 T cells in addition to CD4 T cells. (8) Apoptosis promotes
crosspriming. (9) Autophagy accelerates elimination of VPM1002 and improves antigen presentation and T cell stimulation. (10) IL-1β and IL-18 induce an
inflammatory response. Through these mechanisms, VPM1002 induces an immune response with more depth and breadth than parental BCG (B) Mtb. The genome
of Mtb comprises the region of difference 1 (RD-1) which encodes numerous virulence factors which are absent in BCG. Notably genes for Esx dependent
mechanisms cause perturbation of phagosomal membranes, very similar to VPM1002. For further details see (A). Because the RD-1 encoded gene products are not
degraded after their egress into the cytosol, pathologic consequences prevail. Moreover, RD-1 encoded gene products are not controlled by pH. Hence, inbuilt
safety mechanisms of VPM1002 are absent from Mtb (see also Figure 3).
FIGURE 3 | Safety mechanisms of listeriolysin render VPM1002 less virulent than parental BCG. Listeriolysin contains a PEST-like sequence which promotes its
degradation. (1) Only at acidic pH, listeriolysin is biologically active and hence perturbates the phagosomal membrane. (2) In the cytosol, monomeric listeriolysin
aggregates. (3) Aggregated listeriolysin is degraded by ubiquitin resulting in inactive peptides. (4) Multimeric listeriolysin complexes are formed at the plasma
membrane. (5) These complexes are translocated into autophagosomes by ubiquitin. (6) These listeriolysin complexes are inactivated in the phagosome.
PEST = Proline (P), Gutalate (E), Serine (S), and Threonine (T). Modified from (88–90).
remain TST+/IGRA+ over longer periods of time, if not lifelong.
However, a small group may revert to TST−/IGRA− indicating
that they are capable of eradicating Mtb before they become
permanently infected. The recent BCG revaccination trial on
PoI (73) described above did not reveal significant differences
between BCG-immunized and control groups in early conversion
to IGRA+. Yet, a 45% reduction in sustained IGRA+ (determined
at later time points) was observed in the BCG immunized
group as compared to controls without BCG immunization.
Moreover, observational studies have identified a distinct group
of permanent non-converters (TST−/IGRA−) generally in the
order of 20% (95–98).
Obviously, the described effects could also be due to technical
reasons and the TST−/IGRA− group could be infected with Mtb
but missed by TST/IGRA because these individuals develop a
protective immune response which is not detected by TST and
IGRA. Underlying mechanisms could include antibodies, MAIT
cells, γδ T cells, NK cells and NKT cells (32, 36–45). Furthermore,
it remains unclear whether all TST+/IGRA+ individuals are
indeed Mtb infected or whether at least a subgroup has succeeded
in eliminating Mtb but remains TST+/IGRA+ because of a
strong memory T cell response which persists in absence of Mtb
antigens. Principally, immunology defines memory as a state of
immunity in absence of nominal antigen(s).
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FIGURE 4 | Fate of household contacts of a TB index case. Household contacts of a TB index case are either already latently TB infected (LTBI) or do not show
evidence for immunity against Mtb infection. After sustained contact with a TB index case, the majority of naïve individuals will rapidly convert to LTBI because they
(Continued)
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FIGURE 4 | Continued
mount an immune response against Mtb infection. Most of these early converters will remain LTBI and hence become sustained converters. A small proportion of
early converters reverts to naïve, i.e. devoid of a measurable immune response to Mtb infection. Some naïve individuals will remain permanent non-converters, i.e.
they do not change their status of absent immunity indicating absence of Mtb infection. Finally, some individuals with LTBI will revert to naïve, i.e. they lose their
detectable immune response to Mtb indicating elimination of Mtb. The mechanisms underlying these conversions/reversions remain elusive. (A) Indicates response
in TST/IGRA and (B) depicts resulting conclusions on conversion/reversion (for further details see text).
Another interesting group may arise years after primary
Mtb infection. Whilst many individuals with LTBI remain
TST+/IGRA+ livelong, some individuals revert to TST−/IGRA−.
It is likely that in these individuals, reversion from TST+/IGRA+
to TST−/IGRA− reflects sterile eradication of Mtb. Yet, it cannot
be excluded formally that these individuals remain Mtb infected
and control infection by unknown immune mechanisms not
detected by TST/IGRA such as antibodies and unconventional
T cells. In any case, the permanent non-converters and the
late reverters are highly interesting study groups which provide
the opportunity to gain deeper insights into the mechanisms
of protection against Mtb. TB vaccines which prevent stable
infection with Mtb and thereby prevent LTBI and active TB
disease would be highly desirable. The specific mechanisms
underlying permanent non-conversion and late reversion could
be elucidated by determining transcriptomic, metabolomic
and immunologic markers and signatures which distinguish
permanent non-converters and late reverters from sustained and
livelong reverters, respectively (26, 99).
OUTLOOK AND FUTURE
Over the last decade, the TB vaccine pipeline has significantly
progressed. First, a number of vaccines is ready for clinical
efficacy testing for PoI, PoD, or PoR (see Box 1). This implies
that several vaccine candidates have already proven their safety
and immunogenicity. Second, several positive signals arose from
clinical trials over the last years including proof of concept
that a subunit vaccine empowered by a strong adjuvant can
partially protect against active TB when given post-exposure to
individuals with LTBI (65, 66). Third, BCG revaccination of
Mtb unexposed individuals has provided indirect evidence for
partial prevention of sustained Mtb infection (73). Obviously,
major issues remain to be solved. These include: First, BCG
revaccination outcome was determined by IGRA which measures
canonical T-cell immune responses rather than Mtb infection
per se (see above). This raises the question whether BCG
indeed prevented Mtb infection or whether infection occurred
but was controlled by alternative immune mechanisms such
as antibodies and/or unconventional T cells. Second, the M72
clinical trial did not include BCG vaccination as a positive
control. Third, studies in NHP revealed that different subunit
vaccine constructs including M72, H56, and the CMV vectored
TB vaccine failed to increase protection when given as booster
on BCG prime (70, 71). In sum, there is well justified hope
for better vaccines; but it remains difficult to predict when
and to which degree TB can be controlled by improved
vaccination strategies.
Nassim Nicholas Taleb is best known for describing the Black
Swan Concept which basically includes the notions (100): (i) rare
and improbable events do occur more frequently than we assume;
(ii) these extreme events can have enormous consequences;
(iii) experts generally provide explanations post-hoc which were
not plausible ex-ante. This concept was aptly illustrated by the
financial stock market crisis in 2008 when numerous stock
owners who had gradually accumulated a financial depot went
bankrupt through a single event. The most illustrative description
for the Black Swan concept is the life of a Thanksgiving Day
turkey which is taken care of very well over the first 1000 days
by feeding it with most nourishing food. An observer (including
the turkey if it could do so) could conclude that the quality of life
of this animal increases constantly. Yet, on day 1001, the butcher
kills the animal unexpectedly in preparation for Thanksgiving
Day. Obviously, this is an extreme event with a major impact on
the animal. This scenario can also be turned upside down into a
FIGURE 5 | Possible scenarios of TB vaccine development given that
adequate financial funding is provided for research & development (R&D).
Upper, single step event; Lower, multistep event.
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positive direction, i.e. that an unexpected and improbable event
turns into something markedly better (an event which would
perhaps be better described by the term Pink Swan). With respect
to TB vaccine design, continuous funding into R&D (from basic
research to preclinical and clinical development) will increase
our knowledge about the underlying mechanisms of protection
against TB and how this information can be harnessed for TB
vaccine design (Figure 5).
For long periods of time research crawls, but every now and
then it jumps. By increasing funding, a fertile soil can be prepared
for R&D on better vaccines. Maybe this leads to an extreme
event (a single jump), resulting in a novel vaccine that fits all
purposes. More likely a couple of smaller, yet significant events
will occur which ultimately lead to TB vaccines for different
purposes. The type of vaccine and the time when it will be ready
for clinical licensing remain unclear as expected for a Black/Pink
Swan. Yet, increased funding for R&D will favor chances of
success. Undoubtedly, this cannot be accomplished free of cost;
yet ultimately it will save cost by reducing the enormous expenses
caused by the TB endemic. After all, annual cost for treating
active TB disease globally has been estimated to be in the range
of 2 billion US dollars and the total burden of TB on the global
economy in the order of 100 billion US dollars (101).
It is worth to conclude with a citation from the resolution
adopted by the General Assembly of the United Nations from the
High Level Meeting on the fight against TB in 2018 (1):
“Commit to mobilize sufficient and sustainable financing, with the
aim of increasing overall global investments to 2 billion dollars,
in order to close the estimated 1.3 billion dollar gap in funding
annually for tuberculosis research, ensuring that all countries
contribute appropriately to research and development . . ..”
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